[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. (linkinghub.elsevier.com)

Authors: Tagawa ST … Morris MJ Journal: The Lancet Published: 2026-08-06 DOI: https://doi.org/10.1016/S0140-6736(26)01092-5